Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021

 Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021

Shots:

  • The P-II ELARA study involves assessing the efficacy & safety of Kymriah in adult patients with r/r FL in 30 sites across 12 countries
  • Results: @median follow-up of 11 mos., CRR (66%), ORR (86%) with one-time therapy infusion, median DOR in all responders, PFS & OS were not reached, response rates were consistent across high-risk patient subgroups, estimated DOR in patients with CR and PFS rates @6mos. (94% & 76%), no patient experienced grade 3/4 cytokine release syndrome. The regulatory submissions based on a P-II study is expected in late 2021
  • Kymriah is 1st FDA-approved CAR-T cell therapy for r/r ALL in pediatric & adult patients and r/r adult DLBCL

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Clinical Trials Arena

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post